Abstract: The present disclosure relates to a method for diagnosing Parkinson's disease in which the method includes measuring the expression level of Parkinson's disease-related genes from a subject's nasal mucus sample, a composition for diagnosing Parkinson's disease, and a kit including the same.

Abstract: Disclosed herein are methods of detecting an altered gene expression levels in a subject suspected of having atopic dermatitis. Further described herein are methods of treating atopic dermatitis in a subject having an exhibiting an altered gene expression level.

Abstract: The present invention provides novel compositions and methods for assessing the size of tandem repeat sequences, e.g., telomeres, within a genome, using specially designed Molecular Inversion Probes (MIPs) and reaction conditions.

Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.

Abstract: Methods and kits for diagnosing and/or treating a lower respiratory infection in a subject include obtaining a biological sample from the subject; detecting RNA expression levels of one or more biomarkers in the biological sample and comparing the expression levels of the one or more three biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of the one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.

Abstract: The present invention provides methods of detecting ultraviolet radiation (UVR)-induced skin damage in a subject. The method includes the steps of: a) obtaining a skin sample from the subject; b) analyzing expression levels in the skin sample of UVR-induced differentially expressed genes (DEGs) listed in Table 8 or a subset thereof; and c) comparing the expression levels of the UVR-induced DEGs to a control skin sample; wherein, when the expression levels of the UVR-induced DEGs in the skin sample is above or below the level of each of the UVR-induced DEGs in the control sample, the subject is identified as likely being afflicted with UVR-induced skin damage. Also provided are methods for measuring the effectiveness of a test agent in reducing ultraviolet radiation (UVR)-induced damage.

Abstract: The present invention relates to clonal expansion of somatic cells in subjects, and acquired selective advantage of cell clones during the lifetime of a subject. In particular, the invention relates to methods for predicting the development of cancer based on the observation of specific genetic mutations in somatic cell clones, as well as to methods for treating or preventing cancer in a subject, in which clonal expansion of cells comprising specific modifications is observed.

Abstract: Disclosed are a tumor biomarker and application thereof, and a tumor detection kit. Patients suffering from non-small cell lung cancer, containing an EML4-ALK or SLC34A2-ROS1 fusion gene, have a specific circular RNA in blood. The base sequences of the circular RNA are represented by SEQ ID NOS. 1-6. The circular RNA is associated with non-small cell lung cancer, stably and constantly exists in plasma samples, and has high specificity and effectiveness, and thus can be used as a biomarker for tumor detection. Reagents such as primers and probes for detecting the circular RNA can be used for preparing the tumor detection kit.

Abstract: Immune-modulating genes are provided for prognosis and diagnosis of metastases or reoccurrence of cancer, as well as methods of prognosis, diagnosis, prophylaxis and treatment of cancer metastases.

Abstract: The present invention relates to methods of predicting resistance to heart and skeletal muscle inflammation in salmonids, the method comprising determining the alleles present at a DNA polymorphism in the salmonid and predicting whether or not the salmonid is resistant to heart and skeletal muscle inflammation based on the determination of the alleles. The invention also relates to related methods of detecting, in a sample from a salmonid, the alleles present at a DNA polymorphism associated with resistance to heart and skeletal muscle inflammation, methods for obtaining an indication of risk of a salmonid developing heart and skeletal muscle inflammation, uses of such DNA polymorphisms, and methods of detecting, in a sample from a salmonid, one or more salmonid gene variants.

Abstract: Disclosed herein are gene signature sets expressed by kidney allograft recipients prior to transplant that determine the risk for acute rejection (AR) post-transplant and methods of using the gene signature sets for identifying renal allograft recipients at risk for acute rejection. Also disclosed herein are kits for use in the invention which comprise primer pairs for the gene signature sets.

Abstract: The present invention provides novel markers of treatment response in a subject infected with Mycobacterium, which allow for quantifying treatment impact on the physiologic state of the Mycobacterium.

Abstract: This document provides methods and materials related to treating subjects having specific genetic variations associated with neurological disorders such as Parkinson's disease.

Abstract: The present invention relates to a novel non-invasive method for the diagnosis of a non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, and/or liver fibrosis.

Abstract: Compositions and methods useful for the diagnosis and treatment of juvenile idiopathic arthritis are disclosed.

Abstract: The present invention pertains to a non-invasive method for monitoring transplanted organ status in organ-transplant recipients by determining the ratio of donor derived marker sequences to the marker sequences of the transplant recipient from circulating cell free DNA of the transplant recipients using digital droplet PCR. The invention also determined a normalized threshold value of the total circulating cell free nucleic acids healthy as well as in post-transplantation patients for assessing and monitoring transplanted organ status in organ-transplant recipients.

Abstract: Disclosed are a method for analyzing a melting curve using bi-functional fluorescent PNA probes, a method for diagnosing microsatellite instability (MSI) using the same, and a kit for diagnosing microsatellite instability (MSI) using the same. More particularly, disclosed are a method for analyzing a melting curve, based on the structure of fluorescent PNA probes that bind with different binding forces depending on the number of base mutations deleted using the fluorescent PNA probes capable of specifically binding to regions where the same base is repeated, and a method for rapidly and accurately detecting and analyzing microsatellite instability (MSI) by detecting gene mutation of microsatellite markers caused by base deletion in regions where the same base is repeated using the analysis method and analyzing the number of base mutations thus obtained.

Abstract: Methods for diagnosing propensity to exhibit acquired peripheral neuropathy in dogs are described. The methods and kits test dogs for presence of a disease-associated genomic variant. Presence of the genomic variant indicates an increased likelihood of the dog developing an acquired peripheral neuropathy. This information can be used to guide preemptive clinical treatment of the animal for peripheral neuropathy and to choose dogs for selective breeding programs.

Abstract: The present invention provides an in vitro method for obtaining data useful for diagnosing a cardiomyopathy in a human subject, wherein the method comprises using, as an indicator, the expression levels, obtained from a biological sample isolated from the human subject, preferably a plasma sample, of one or more of the following miRNAs miR-721 and/or miR-155); and obtaining a result of the method by comparing the expression levels of said one or more miRNAs with a reference value or with the expression levels of a control, indicator of the absence of cardiomyopathy.

Abstract: Disclosed herein are methods and compositions such as primers, primer pairs, and kits for typing KIR2DL1, KIR2DL2, Sand KIR2DL3 alleles. The compositions and methods disclosed herein are useful in the selection of most appropriate donors for HCT.